PTPA and posterior cortical atrophy: Together with emerging orally bioavailable PP2A reactivating compounds, exhibiting profound antitumour activity in in vivo PCa models [52], these results clearly emphasize the future importance of comprehensive understanding of PP2A biology for management of aggressive PCa.